INOVIQ Ltd (ASX:IIQ – Get Rating) insider Philip (Phil) Powell bought 20,000 shares of the firm's stock in a transaction on Monday, March 6th. The stock was acquired at an average cost of A$0.57 ($0.38) per share, with a total value of A$11,400.00 ($7,651.01).

Philip (Phil) Powell also recently made the following trade(s):

• On Wednesday, March 1st, Philip (Phil) Powell purchased 18,518 shares of INOVIQ stock. The shares were acquired at an average cost of A$0.54 ($0.36) per share, with a total value of A$9,999.72 ($6,711.22).
• On Friday, March 3rd, Philip (Phil) Powell purchased 19,481 shares of INOVIQ stock. The shares were acquired at an average cost of A$0.56 ($0.38) per share, with a total value of A$10,909.36 ($7,321.72).

INOVIQ Stock Performance

The company has a debt-to-equity ratio of 3.73, a current ratio of 5.28 and a quick ratio of 9.52.

About INOVIQ

(Get Rating)

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample.

Featured Stories

• FuelCell Energy Gains Traction, Shares Surge
• Solo Brands May Remind Investors Why Cash is King
• Someone Is Buying The Dip In MongoDB
• Cameco: Is the New Uranium Bull Market Here to Stay?
• Etsy Stock: Crafty Bargain or Piece of Junk?

Receive News & Ratings for INOVIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INOVIQ and related companies with MarketBeat.com's FREE daily email newsletter.